Alpha Tau Medical (NASDAQ:DRTS - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $9.00 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 244.83% from the stock's current price. HC Wainwright also issued estimates for Alpha Tau Medical's FY2025 earnings at ($0.53) EPS.
Alpha Tau Medical Stock Up 0.4 %
Shares of DRTS traded up $0.01 during mid-day trading on Monday, reaching $2.61. The company had a trading volume of 21,600 shares, compared to its average volume of 49,023. The stock has a market capitalization of $182.50 million, a P/E ratio of -6.07 and a beta of 0.87. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $4.39. The stock has a 50 day moving average of $3.21 and a two-hundred day moving average of $2.79.
Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). On average, sell-side analysts expect that Alpha Tau Medical will post -0.45 earnings per share for the current year.
Institutional Trading of Alpha Tau Medical
Several institutional investors have recently bought and sold shares of DRTS. Levin Capital Strategies L.P. increased its holdings in Alpha Tau Medical by 2.3% in the 4th quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock worth $975,000 after acquiring an additional 7,189 shares in the last quarter. Northern Trust Corp raised its position in shares of Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after purchasing an additional 25,770 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Alpha Tau Medical by 188.7% in the 4th quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock valued at $127,000 after buying an additional 26,800 shares in the last quarter. 2.65% of the stock is owned by institutional investors and hedge funds.
Alpha Tau Medical Company Profile
(
Get Free Report)
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Further Reading
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
